US OptionsDetailed Quotes
FOLD241220P14000
- 2.12
- 0.000.00%
15min DelayClose Nov 29 13:00 ET
0.00High0.00Low
2.12Open2.12Pre Close0 Volume0 Open Interest14.00Strike Price0.00Turnover0.00%IV-19.04%PremiumDec 20, 2024Expiry Date4.02Intrinsic Value100Multiplier21DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.56Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Amicus Therapeutics Stock Discussion
Sign in to post a comment
$Amicus Therapeutics (FOLD.US)$
Enter 9.88 Exit 1 10.85 Exit 2 12.1 Exit 3 14.5
Stop loss according to risk
Enter 9.88 Exit 1 10.85 Exit 2 12.1 Exit 3 14.5
Stop loss according to risk
3
» Holdings: 112
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings (CERE.US)$
$Amicus Therapeutics (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$Medtronic (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
...
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings (CERE.US)$
$Amicus Therapeutics (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$Medtronic (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
...
8
Despite Amicus Therapeutics' recent share price uptick and steady revenue growth, the market's high expectations are reflected in the share price fall over the past three years. The company's 3.2% total shareholder return over the last twelve months falls short of the market return.
1
Investors might overlook Amicus Therapeutics' below industry-level growth forecast, risking future disappointment if the P/S ratio falls in line with the growth outlook. Moderate P/S ratio poses a risk as weaker revenue outlook might lead to share price drop.
$Amicus Therapeutics (FOLD.US)$ FDA approval 🚀🙏🏻
$Amicus Therapeutics (FOLD.US)$ News halt...... watching
1
$Amicus Therapeutics (FOLD.US)$ Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis.
GALACTIC-1 trial did not meet its primary endpoint.
Galecto to discontinue the development of GB0139.
GALACTIC-1 trial did not meet its primary endpoint.
Galecto to discontinue the development of GB0139.
$Amicus Therapeutics (FOLD.US)$ Following the sale, the chief executive officer now owns 689,618 shares of the company's stock, valued at approximately $7,261,677.54. he just needed the money for somthing if it was bad news we dont know yet then he would have sold way more
No comment yet
Tonyco OP :
Tonyco OP :
Tonyco OP :